GSK 2334470,
GSK-2334470,
GSK2334470,
GSK2334470,
1227911-45-6,
GSK 2334470,
GSK-2334470,
CHEMBL1765740,
(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide,
(3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide,
QLPHOXTXAKOFMU-WBVHZDCISA-N,
MLS006011255,
GTPL8008,
SCHEMBL1317022,
C25H34N8O,
CHEBI:91465,
AOB6843,
DTXSID40673111,
EX-A1544,
2445AH,
BDBM50341243,
s7087,
ZINC68203217,
AKOS024458000,
CS-0917,
QC-8425,
SB19280,
AS-16973,
BC600491,
HY-14981,
SMR004703010,
AB0097232,
FT-0696643,
SW219485-1,
W-5846,
GSK 2334470;GSK-2334470,
GSK2334470, >=98% (HPLC),
J-004855,
BRD-K70642949-001-01-1,
3-Piperidinecarboxamide, 1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-, (3S,6R)-,
D0EU1R,
PDK1 inhibitors, GlaxoSmithKline,
A12767,
(3S,6R)-;(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide,